TrialCancer2020

Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study.

Panpan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.